De Dios-Figueroa G Tonantzin, Aguilera-Márquez Janette Del Rocío, García-Uriostegui Lorena, Hernández-Gutiérrez Rodolfo, Camacho-Villegas Tanya A, Lugo-Fabres Pavel H
Unidad de Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Guadalajara 44270, Jalisco, Mexico.
CONAHCYT-Departamento de Madera, Celulosa y Papel, Universidad de Guadalajara (UDG), Guadalajara 44100, Jalisco, Mexico.
Polymers (Basel). 2023 Sep 11;15(18):3726. doi: 10.3390/polym15183726.
Epidermal growth factor receptor 2 (HER2) is the second target molecule most commonly used in breast cancer treatment. Both recurrence and metastasis are still deadly for HER2+ breast cancer patients. Hydrogels can be an option for developing three-dimensional (3D) cell culture systems that resemble tumor features better than monolayer cultures and could be used for preclinical screening for new biotherapeutics. Biopolymers (gelatin and alginate) were used to develop a hydrogel capable of encapsulating living HER2+ breast cancer cells BT-474/GFP. The hydrogel was physicochemically characterized, and the viability of embedded cells was evaluated. The hydrogel developed had suitable physical properties, with swelling of 38% of its original mass at 20 h capacity and pore sizes between 20 and 125 µm that allowed cells to maintain their morphology in a 3D environment, in addition to being biocompatible and preserving 90% of cell viability at 10 days. Furthermore, encapsulated BT-474/GFP cells maintained HER2 expression that could be detected by the Trastuzumab-fluorescent antibody, so this hydrogel could be used to evaluate new HER2-targeted therapies.
表皮生长因子受体2(HER2)是乳腺癌治疗中第二常用的靶分子。复发和转移对HER2阳性乳腺癌患者来说仍然是致命的。水凝胶可以作为开发三维(3D)细胞培养系统的一个选择,该系统比单层培养更能模拟肿瘤特征,可用于新生物治疗药物的临床前筛选。生物聚合物(明胶和藻酸盐)被用于开发一种能够封装活的HER2阳性乳腺癌细胞BT-474/GFP的水凝胶。对该水凝胶进行了物理化学表征,并评估了包埋细胞的活力。所开发的水凝胶具有合适的物理性质,在20小时时其质量膨胀38%,孔径在20至125微米之间,这使得细胞能够在三维环境中保持其形态,此外还具有生物相容性,在10天时能保持90%的细胞活力。此外,包封的BT-474/GFP细胞维持了HER2表达,可通过曲妥珠单抗荧光抗体检测到,因此这种水凝胶可用于评估新的HER2靶向疗法。